Results 21 to 30 of about 21,820 (216)
Антибиотики и Химиотерапия, 2021 The wide spread of carbapenemases among gram-negative bacteria of the Enterobacterales order in hospitals around the world, including Russia, creates great difficulties in the effective use of antibiotics for these infections in the ICU.
S. V. Yakovlev
doaj +1 more source
, 2021 Objective: To systematically review and compare the efficacy and posttreatment resistance of ceftazidime-avibactam therapy and ceftazidime-avibactam-based combination therapy in patients with Gram-negative pathogens.Methods: PubMed, Embase, Web of ...
Xiangning Huang (5216384) +6 more
core +1 more source
Revista Española de Quimioterapia, 2022 The increase in nosocomial infections by beta-lactamase producing Gram-negative bacilli constitutes a therapeutic challenge. The combination of ceftazidime-avibactam offers a very interesting therapeutic option for nosocomial pneumonia caused by extended-spectrum beta-lactamase-producing Klebsiella pneumoniae, multidrug-resistant Pseudomonas aeruginosa,
openaire +2 more sources
Microorganisms, 2020 Increasing carbapenem resistance rates worldwide underscored the urgent need of novel antimicrobials. Ceftazidime–avibactam and aztreonam–avibactam combinations are developed to combat carbapenem resistance, but biological and geographic variations must ...
Tsung-Ying Yang +10 more
doaj +1 more source
Ceftazidime/Avibactam Resistance in Carbapenemase-Producing Klebsiella pneumoniae
Emerging Infectious Diseases, 2023 We identified a novel ceftazidime/avibactam resistance mechanism in sequence type 11 Klebsiella pneumoniae carbapenemase 2–producing K. pneumoniae.
Qiaozhen Cui +6 more
doaj +1 more source
Antimicrobial Resistance and Infection Control, 2020 Background This study reports the global trends of antimicrobial susceptibility to ceftaroline and ceftazidime–avibactam using data from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program between 2012 and 2016.
Hui Zhang +12 more
doaj +1 more source
Analysis of the clinical application of ceftazidime-avibactam in China
Journal of Infection and Public Health, 2022 The efficacy and safety of ceftazidime-avibactam were mainly reported in phase II and phase III clinical trials, rarely in the real-world study. The limited real-world study which evaluated the clinical response of this drug shown inconsistent results.
Qing Wang, Ping Xu, Yangang Zhou
openaire +3 more sources
, 2021 Objective: To systematically review and compare the efficacy and posttreatment resistance of ceftazidime-avibactam therapy and ceftazidime-avibactam-based combination therapy in patients with Gram-negative pathogens.Methods: PubMed, Embase, Web of ...
Xiangning Huang (5216384) +6 more
core +1 more source
BMC Microbiology, 2023 Abstract Background Ceftazidime-avibactam (CZA) improves treatment outcomes for infections caused by carbapenem-resistant organisms, but has led to serious bacterial resistance. Acetylcysteine (NAC) is an approved medication that protects the respiratory tract through antioxidant and anti-inflammatory effects.
Zeyu Huang +7 more
openaire +3 more sources
, 2022 This study reported the identification of a novel ceftazidime-avibactam-resistant KPC-2 variant, KPC-123, in a Citrobacter koseri isolated from a patient in a Chinese hospital following ceftazidime-avibactam treatment of infection caused by OXA-232 ...
Weiyi Shen (1835500) +3 more
core +1 more source